Search
Blinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigational[L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.[A254826] … MRD) greater than or equal to 0.1% in adults and children.
Products: BLINCYTO POWDER FOR INFUSION 35 MCG/VIAL, BLINCYTO (Blinatumomab) for injection 35 mcg/vialDimercaprol
go.drugbank.com/drugs/DB06782ApprovedIn addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. … Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects.
Categories: Compounds used in a research, industrial, or household settingInternational brands: Bal In Oil InjectionBaloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[A39895, A251755] It is a prodrug of [baloxavir] [L42855] with an improved absorption profile than its active metabolite due to the addition of a phenolic hydroxyl group to its structure. … Baloxavir marboxil is an antiviral drug used to treat influenza. More specifically, it is a first-in-class cap-dependent endonuclease inhibitor that works to block influenza virus proliferation.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UsePeramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalPeramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseRiltozinameran
go.drugbank.com/drugs/DB17095ApprovedInvestigationalIt is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419] … The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021.
Mixtures: Comirnaty Original/omicron Ba.1Tipiracil
go.drugbank.com/drugs/DB09343ApprovedInvestigationalTipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, OCT2 Substrates with a Narrow Therapeutic IndexInfluenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15520ApprovedWithdrawnInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Synonyms: Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (UV, formaldehyde inactivated)Mixtures: INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 ML, INFLUVAC, suspension for injection 0.5mlToripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalIt was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsLithium cation
go.drugbank.com/drugs/DB01356ApprovedInvestigationalWithdrawnThe active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several … It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches.
Synonyms: LI, Li(+)Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting